JAVELIN Bladder 100: Phase III Trial of Maintenance Avelumab After First-line Platinum Chemotherapy in Advanced Urothelial Carcinoma

May 29-31, 2020; Online at meetings.asco.org/am
Maintenance avelumab plus BSC significantly prolonged OS in the overall population and in patients with PD-L1–positive disease.
Format: Microsoft PowerPoint (.ppt)
File Size: 247 KB
Released: June 3, 2020

Acknowledgements

Provided by Clinical Care Options, LLC.

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AstraZeneca
Bayer HealthCare Pharmaceuticals Inc.
Bristol-Myers Squibb
Exelixis
Pfizer, Inc. and EMD Serono

Related Content

Download this expert slideset on strategies for developing compassionate care plans with transgender patients based on their current anatomy

person default Lauren Radziejewski, DNP Released: October 4, 2022

Phase III COSMIC-313: addition of cabozantinib to nivolumab plus ipilimumab in previously untreated patients with IMDC intermediate- or poor-risk advanced RCC, presented at ESMO 2022 and reported by Clinical Care Options (CCO)

Released: September 22, 2022

Phase I/II EV-103 cohort K: enfortumab vedotin with or without pembrolizumab as first-line treatment in cisplatin-ineligible locally advanced urothelial cancer, presented at ESMO and reported by Clinical Care Options (CCO)

Released: September 22, 2022

CheckMate 274: pretreatment tumor and immune features and DFS with adjuvant nivolumab in high-risk muscle-invasive UC following radical resection, presented at ESMO 2022 and reported by Clinical Care Options (CCO)

Released: September 22, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings